<p>Thyroid cancer MR molecular imaging via SHP2-targeted nanoparticles</p>

Abstract

BackgroundMolecular imaging has generated a great demand to develop targeted contrast agents for MR imaging.Materials and methodsIn this study, we synthesized Src homology 2-containing phosphotyrosine phosphatase 2 (SHP2)-targeted and polylactic-co-glycolic acid–-based nanoparticles (NPs), which encapsulated perfluoropentane and being chelated with gadolinium (Gd3+) as an efficient molecular probe for targeting MR imaging on thyroid carcinoma.ResultsThese NPs displayed practical properties and favorable biocompatibility in vitro. Furthermore, they showed abilities to specifically target thyroid cancer and enhance MRI as a contrast agent in both in vitro and in vivo experiments.ConclusionThis novel MR molecular imaging based on this SHP2-targeted contrast agent provides a useful and non-invasive method for the early detection of thyroid carcinoma.

Next-Generation Molecular Imaging of Thyroid Cancer

“…Hu et al created an SHP2-targeted core-shell nanoparticle chelated with the contrast agent Gd 3+ on the surface (NPs-SHP2). Similar to the EGFR-targeted nanoparticles mentioned previously, PFP-based LIFU can facilitate the probe carrying contrast agent been accumulated in the thyroid tumor area for enhanced MRI [155] (Figure 16).…”

“…Nanoparticles have been emerging with widespread attention in MI, drug delivery, and disease treatment. Nanoparticles have brought their potential as MI agents to TC, primarily through their applicability in fluorescence imaging, ultrasound, and MRI [154,155]. These modalities enable nanoparticles to accumulate in cells by activation through US, light, temperature, and pH change, depending on the nanoparticle structures and their surface molecules.…”

“…Antibodies and peptides are the primary ligand choices due to their specific affinity to targets in TC fields. Although applications of targeted nanoparticles in TC have so far been limited, there have been publications investigating nanoparticles conjugated to antibodies targeting epidermal growth factor receptor (EGFR) or Src homology 2 (SH2) domain-containing phosphatase 2 (SHP2) [154,155]. xenograft model.…”

Nanomaterials: a promising multimodal theranostics platform for thyroid cancer

“…2B and C). 51 Although the use of nanomaterials as MRI imaging enhancers in the diagnosis of thyroid cancer is promising, further research is still needed to explore their potential. Additionally, research on multi-mode imaging using nanomaterials should be deeply studied.…”

Advances in Biomarker-Driven Targeted Therapies in Thyroid Cancer

“…Au–Ag @ PDA NPs can accumulate in the mitochondria, leading to mitochondrial dysfunction with downregulation of dihydroorotate dehydrogenase resulting in an upregulation of p53 and cell cycle arrest, ultimately inhibiting the proliferation of thyroid cancer cells [ 74 ]. More recently, the use of nanoparticles for thyroid cancer imaging has been also explored; for instance, Src homology 2-containing phosphotyrosine phosphatase 2 (SHP2)-targeted NPs have been used for a molecular probe for thyroid cancer [ 75 ]. An advanced study developed a novel theragnostic nanoplatform for controllable doxorubicin delivery in thyroid cancer [ 76 ].…”